Stoke Therapeutics (STOK) Cash from Operations Growth (5y) (2023 - 2026)
Stoke Therapeutics (STOK) Cash from Operations Growth (5y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.64% |
| Dec 31, 2025 | -22.74% |
| Sep 30, 2025 | -22.80% |
| Jun 30, 2025 | -21.39% |
| Mar 31, 2025 | 70.10% |
| Dec 31, 2024 | -17.85% |
| Sep 30, 2024 | -21.85% |
| Jun 30, 2024 | -22.74% |
| Mar 31, 2024 | -30.33% |
| Dec 31, 2023 | -42.49% |
| Sep 30, 2023 | -41.52% |